November 23, 2025 – Patient Worthy

Tonix Advances Novel Oxytocin Treatment for Prader-Willi Syndrome into Clinical Testing

Post author:Bree Clare
Post published:November 23, 2025
Post category:Prader-Willi Syndrome

Tonix Pharmaceuticals announced plans to initiate Phase 2 clinical trials in 2026 for TNX-2900, an innovative intranasal oxytocin formulation designed to treat Prader-Willi Syndrome (PWS), a rare genetic disorder characterized…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More